These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35899664)

  • 21. Should all advanced BRCA-mutated patients in response to first-line platinum-based chemotherapy receive PARPi + bevacizumab as maintenance therapy?
    Turinetto M; Ray-Coquard I; Gourley C
    ESMO Open; 2024 May; 9(5):102983. PubMed ID: 38663167
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
    Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic histologique et moléculaire des cancers de l'ovaire - recommandations pour la pratique clinique Saint-Paul 2021: Histological and molecular diagnosis of ovarian.
    Genestie C; Gladieff L; Frère-Belda ML; Lortholary A; Vaur D; Treilleux I; Lyonnet DS
    Bull Cancer; 2021 Dec; 108(9S1):S33-S38. PubMed ID: 34955160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Not Available].
    Gladieff L; Lyonnet DS; Lortholary A; Leary A; Genestie C; Ray-Coquard I
    Bull Cancer; 2017 May; 104 Suppl 1():S16-S23. PubMed ID: 28625311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Niraparib for the treatment of ovarian cancer.
    Kanjanapan Y; Lheureux S; Oza AM
    Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    Vergote I; Ray-Coquard I; Anderson DM; Cantuaria G; Colombo N; Garnier-Tixidre C; Gilbert L; Harter P; Hettle R; Lorusso D; Mäenpää J; Marth C; Matsumoto K; Ouwens M; Poveda A; Raspagliesi F; Rhodes K; Rubio Pérez MJ; Shapira-Frommer R; Shikama A; Sikorska M; Moore K; DiSilvestro P
    Eur J Cancer; 2021 Nov; 157():415-423. PubMed ID: 34597975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer.
    Haddad FG; Karam E; Moujaess E; Kourie HR
    Pharmacogenomics; 2020 Jul; 21(10):721-727. PubMed ID: 32597301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line PARP inhibitors in ovarian cancer: summary of an
    Banerjee S; Gonzalez-Martin A; Harter P; Lorusso D; Moore KN; Oaknin A; Ray-Coquard I
    ESMO Open; 2020 Nov; 5(6):e001110. PubMed ID: 33310779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
    Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB
    BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review.
    Gadducci A; Cosio S
    Anticancer Res; 2021 Oct; 41(10):4673-4685. PubMed ID: 34593415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
    Moss HA; Perhanidis JA; Havrilesky LJ; Secord AA
    Gynecol Oncol; 2021 Oct; 163(1):50-56. PubMed ID: 34301411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
    Gong H; Nie D; Huang Y; Li Z
    Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P
    N Engl J Med; 2018 Dec; 379(26):2495-2505. PubMed ID: 30345884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PARP inhibitors in ovarian cancer.
    Ledermann JA
    Ann Oncol; 2016 Apr; 27 Suppl 1():i40-i44. PubMed ID: 27141070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.
    Montero-Macias R; Koual M; Crespel C; Le Frére-Belda MA; Hélène HB; Nguyen-Xuan HT; Garinet S; Perkins G; Balay V; Durdux C; Florin M; Péré H; Bats AS
    J Med Case Rep; 2021 Apr; 15(1):210. PubMed ID: 33888155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.